EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	0	(2002/0172967).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/06/05 11:45
L2	0	(2002/00172967).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/06/05 11:43
L3	135	(562/622).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/06/05 13:43
L4	544	(514/575).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/06/05 11:43
L5	20430	benzamide	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/06/05 12:23
L6	641	L3 or L4	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/06/05 11:43
L7	2	("20020172967").PN.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/06/05 11:43
L8	2	("5700811").PN.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/06/05 11:43
L9	2	("5369108").PN.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/06/05 11:43
L10	2	("6087367").PN.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/06/05 11:43
L11	38	L3 and L4	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/06/05 11:43

EAST Search History

L12	113	L5 and L6	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/06/05 11:43
L13	0	(2002/0172967).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/06/05 11:45
L14	15	(benzamide and (hydoxamic or hydroxamate)).clm.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/06/05 12:31
L16	339	(562/621).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/06/05 13:44
L18	37	l5 and l16	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/06/05 13:45

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 3	JAN 16	CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS 4	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS 5	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 6	JAN 22	CA/CAplus updated with revised CAS roles
NEWS 7	JAN 22	CA/CAplus enhanced with patent applications from India
NEWS 8	JAN 29	PHAR reloaded with new search and display fields
NEWS 9	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 10	FEB 15	PATDPASPC enhanced with Drug Approval numbers
NEWS 11	FEB 15	RUSSIAPAT enhanced with pre-1994 records
NEWS 12	FEB 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS 13	FEB 26	MEDLINE reloaded with enhancements
NEWS 14	FEB 26	EMBASE enhanced with Clinical Trial Number field
NEWS 15	FEB 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS 16	FEB 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 17	FEB 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases
NEWS 18	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 19	MAR 16	CASREACT coverage extended
NEWS 20	MAR 20	MARPAT now updated daily
NEWS 21	MAR 22	LWPI reloaded
NEWS 22	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS 23	APR 02	JICST-EPLUS removed from database clusters and STN
NEWS 24	APR 30	GENBANK reloaded and enhanced with Genome Project ID field
NEWS 25	APR 30	CHEMCATS enhanced with 1.2 million new records
NEWS 26	APR 30	CA/CAplus enhanced with 1870-1889 U.S. patent records
NEWS 27	APR 30	INPADOC replaced by INPADOCDB on STN
NEWS 28	MAY 01	New CAS web site launched
NEWS 29	MAY 08	CA/CAplus Indian patent publication number format defined
NEWS 30	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 31	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS 32	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS 33	MAY 21	CA/CAplus enhanced with additional kind codes for German patents
NEWS 34	MAY 22	CA/CAplus enhanced with IPC reclassification in Japanese patents

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:28:35 ON 05 JUN 2007

=> le reg
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:28:46 ON 05 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 4 JUN 2007 HIGHEST RN 936539-19-4
DICTIONARY FILE UPDATES: 4 JUN 2007 HIGHEST RN 936539-19-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> e Benzamide, 4-(benzoylamino)-N-hydroxy-/cn

E1	1		BENZAMIDE, 4-(BENZOYLAMINO)-N-HEPTYL-/CN
E2	1		BENZAMIDE, 4-(BENZOYLAMINO)-N-HEXYL-/CN
E3	1	-->	BENZAMIDE, 4-(BENZOYLAMINO)-N-HYDROXY-/CN
E4	1		BENZAMIDE, 4-(BENZOYLAMINO)-N-METHYL-/CN
E5	1		BENZAMIDE, 4-(BENZOYLAMINO)-N-METHYL-N-(2-(1-PIPERIDINYL)PHENYL)-/CN
E6	1		BENZAMIDE, 4-(BENZOYLAMINO)-N-METHYL-N-(2-(4-PHENYL-1-PIPERIDINYL)-4-PYRIMIDINYL)-/CN
E7	1		BENZAMIDE, 4-(BENZOYLAMINO)-N-METHYL-N-(2-(4-PHENYL-1-PIPERIDINYL)-4-PYRIMIDINYL)-, MONO(4-METHYLBENZENESULFONATE)/CN
E8	1		BENZAMIDE, 4-(BENZOYLAMINO)-N-METHYL-N-(PHENYLMETHYL)-/CN
E9	1		BENZAMIDE, 4-(BENZOYLAMINO)-N-METHYL-N-PHENYL-/CN
E10	1		BENZAMIDE, 4-(BENZOYLAMINO)-N-OCTYL-/CN

```
E11          1   BENZAMIDE, 4-(BENZOYLAMINO)-N-PENTYL-/CN
E12          1   BENZAMIDE, 4-(BENZOYLAMINO)-N-PHENYL-/CN

=> e3
L1           1 "BENZAMIDE, 4-(BENZOYLAMINO)-N-HYDROXY-"/CN

=> d l1

L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2007 ACS on STN
RN   847249-45-0  REGISTRY
ED   Entered STN:  25 Mar 2005
CN   Benzamide, 4-(benzoylamino)-N-hydroxy- (9CI)  (CA INDEX NAME)
MF   C14 H12 N2 O3
SR   CA
LC   STN Files:   CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

               4 REFERENCES IN FILE CA (1907 TO DATE)
               4 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     7.35       7.56

FILE 'CAPLUS' ENTERED AT 12:29:36 ON 05 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```


Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.


```
FILE COVERS 1907 - 5 Jun 2007  VOL 146 ISS 24
FILE LAST UPDATED: 4 Jun 2007  (20070604/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> l1
L2           4 L1
```

=> d l2 1-4 ti fbib abs

L2 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
TI Hydroxamic acid derivative histone deacetylase inhibitors, and their therapeutic use
AN 2006:333299 CAPLUS
DN 144:343645
TI Hydroxamic acid derivative histone deacetylase inhibitors, and their therapeutic use
IN Chakravarty, Prasun K.; Kuo, Howard; Matthews, Jay M.; Meinke, Peter T.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006017214	A2	20060216	WO 2005-US24512	20050708
WO 2006017214	A3	20060601		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
			US 2004-587233P	P 20040712
AU 2005271841	A1	20060216	AU 2005-271841	20050708
			US 2004-587233P	P 20040712
			WO 2005-US24512	W 20050708
CA 2573369	A1	20060216	CA 2005-2573369	20050708
			US 2004-587233P	P 20040712
			WO 2005-US24512	W 20050708
EP 1789381	A2	20070530	EP 2005-770022	20050708
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
			US 2004-587233P	P 20040712
			WO 2005-US24512	W 20050708
IN 2007DN01003	A	20070427	IN 2007-DN1003	20070207
			US 2004-587233P	P 20040712
			WO 2005-US24512	W 20050708

OS MARPAT 144:343645
AB The invention discloses hydroxamic acid derivs. that are inhibitors of histone deacetylase. The compds. are useful for treating cellular proliferative diseases, including cancer. Further, the compds. are useful for treating neurodegenerative diseases, schizophrenia, and stroke, among other diseases. The compds. also have antiprotozoal properties. Compound preparation is included.

L2 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
TI Structure-Based Optimization of Phenylbutyrate-Derived Histone Deacetylase Inhibitors
AN 2005:604284 CAPLUS
DN 143:259486
TI Structure-Based Optimization of Phenylbutyrate-Derived Histone Deacetylase Inhibitors
AU Lu, Qiang; Wang, Da-Sheng; Chen, Chang-Shi; Hu, Yuan-Dong; Chen,

Ching-Shih
CS Division of Medicinal Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH, 43210, USA
SO Journal of Medicinal Chemistry (2005), 48(17), 5530-5535
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
OS CASREACT 143:259486
AB Previously, the authors developed a strategy to develop a novel class of histone deacetylase (HDAC) inhibitors by tethering short-chain fatty acids with Zn2+-chelating motifs, which led to N-hydroxy-4-(4-phenylbutyryl-amino)benzamide (HTPB), a hydroxamate-tethered phenylbutyrate derivative with sub-micromolar potency in inhibiting HDAC activity and cancer cell proliferation. In this study, the authors carried out structure-based optimization of HTPB by using the framework generated by the structure of histone deacetylase-like protein (HDLP)-trichostatin A (TSA) complexes. Docking of HTPB into the HDLP binding domain suggested that the hydrophobic microenvironment encompassed by Phe-198 and Phe-200 could be exploited for structural optimization. This premise was corroborated by the greater potency of (S)-(+)-N-hydroxy-4-(3-methyl-2-phenylbutyrylamino)-benzamide [(S)-11] (IC50 in HDAC inhibition, 16 nM), of which the iso-Pr moiety was favorable in interacting with this hydrophobic motif. (S)-11 at concns. as low as 0.1 μM was effective in causing histone hyperacetylation and p21WAF/CIP1 overexpression and suppressing proliferation in cancer cells.
RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
TI Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors and their use as anticancer agents
AN 2005:540452 CAPLUS
DN 143:55641
TI Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors and their use as anticancer agents
IN Chen, Ching-Shih; Qiang, Lu
PA The Ohio State University Research Foundation, USA
SO PCT Int. Appl., 90 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2005055928	A2	20050623	WO 2004-US40211		20041201
	WO 2005055928	A3	20051006			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				US 2003-526348P	P	20031202
	AU 2004296764	A1	20050623	AU 2004-296764		20041201
				US 2003-526348P	P	20031202
				WO 2004-US40211	W	20041201
	CA 2552279	A1	20050623	CA 2004-2552279		20041201
				US 2003-526348P	P	20031202

				WO 2004-US40211	W 20041201
	EP 1696898	A2	20060906	EP 2004-812666	20041201
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
				US 2003-526348P	P 20031202
				WO 2004-US40211	W 20041201

OS CASREACT 143:55641; MARPAT 143:55641

AB The invention relates to histone deacetylase (HDAC) inhibitors including Zn2+-chelating motifs, based on short-chain fatty acids. Preparation of the HDAC inhibitors is described. Some of the HDAC inhibitors displayed antiproliferative activities at sub-μM concns. and can be used as anticancer agents. The compds. performed well in in vitro and in vivo tests.

L2 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

TI Preparation of arylhydroxamates as elastase and collagenase expression inhibitors for preventing skin aging.

AN 2005:182616 CAPLUS

DN 142:279954

TI Preparation of arylhydroxamates as elastase and collagenase expression inhibitors for preventing skin aging.

IN Rho, Ho Sik; Baek, Heung Soo; Kim, Su Jong; Kim, Su Nam; Chae, Byung Geun; Lee, Byoung Seok; Kim, Bae Hwan; Choi, Gyu Ho; Son, Eui Dong; Lee, Hae Kwang; Lee, Hye Won; Cho, Jun-cheol; Kim, Duck Hee; Chang, Ih Seop; Lee, Ok Sub

PA Amorepacific Corporation, S. Korea

SO PCT Int. Appl., 58 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005019162	A1	20050303	WO 2004-KR2143	20040826
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				KR 2003-59177	A 20030826
				KR 2004-20401	A 20040325
				KR 2004-54886	A 20040714
	KR 2006005892	A	20060118	KR 2004-54886	20040714
	EP 1660437	A1	20060531	EP 2004-774404	20040826
	R: FR				
				KR 2003-59177	A 20030826
				KR 2004-20401	A 20040325
				KR 2004-54886	A 20040714
				WO 2004-KR2143	W 20040826
	CN 1839115	A	20060927	CN 2004-80024139	20040826
				KR 2003-59177	A 20030826
				KR 2004-20401	A 20040325
				KR 2004-54886	A 20040714
				WO 2004-KR2143	W 20040826
	JP 2007503430	T	20070222	JP 2006-524575	20040826
				KR 2003-59177	A 20030826
				KR 2004-20401	A 20040325
				KR 2004-54886	A 20040714

				WO 2004-KR2143	W 20040826
US 2006252834	A1	20061109		US 2006-595124	20060615
				KR 2003-59177	A 20030826
				KR 2004-20401	A 20040325
				KR 2004-54886	A 20040714
				WO 2004-KR2143	W 20040826

OS MARPAT 142:279954
GI



AB Title compds. [I; R1 = adamantyl, Q1; R5, R6 = H, alkyl, cycloalkyl; R2 = CONH, NHCO, CONR7, NR7CO; R7 = alkyl; R3 = (CH)n; n = 0, 1; R4 = H, alkyl], were prepared Thus, 4-(phenylcarbonylamino)benzoic acid (preparation given) in pyridine at 10° was treated dropwise with Et chloroformate followed by stirring for 2 h at room temperature to give the anhydride. This was added to NH2OH.HCl in pyridine at 10° followed by stirring for 30 min. to give 65% N-[4-(N-hydroxycarbamoyl)phenyl]benzamide. The latter reduced collagenase expression in vitro to 78% of controls, vs. 85% for retinol.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT